A 62-year-old woman from Bangalore undergoes total abdominal hysterectomy with bilateral salpingo-oophorectomy and pelvic lymph node dissection for grade 1 endometrial adenocarcinoma with myometrial invasion limited to the inner third. Final histopathology shows no lymphovascular space invasion (LVSI), negative lymph nodes (0/15), and negative peritoneal cytology. She has no other risk factors. What is the most appropriate next step?

Explanation

## Adjuvant Therapy Decision in Low-Risk Endometrial Carcinoma ### Risk Stratification This patient has **stage IA, grade 1** disease with favorable prognostic features: | Feature | Status | Significance | |---------|--------|-------------| | Grade | 1 (low) | Favorable | | Myometrial invasion | Inner third only (≤50%) | Favorable | | LVSI | Absent | Favorable | | Lymph node status | Negative | Favorable | | Peritoneal cytology | Negative | Favorable | | Age | 62 years | No extreme age | **Key Point:** This patient has **low-risk early-stage endometrial cancer** with no adverse features [cite:Harrison 21e Ch 99]. ### Management Algorithm for Stage IA, Grade 1 ```mermaid flowchart TD A[Stage IA, Grade 1 EC]:::outcome --> B{Adverse features?}:::decision B -->|LVSI, high age, or other risk| C[Adjuvant brachytherapy]:::action B -->|No adverse features| D[Observation alone]:::action C --> E[Vaginal brachytherapy]:::outcome D --> F[Clinical follow-up only]:::outcome ``` ### Why Observation is Appropriate **High-Yield:** Low-risk endometrial cancers (stage IA, grade 1, no LVSI, negative nodes) have excellent prognosis (>95% 5-year survival) without adjuvant therapy. Observation avoids unnecessary treatment toxicity [cite:Robbins 10e Ch 19]. **Clinical Pearl:** The GOG-99 trial demonstrated that adjuvant vaginal brachytherapy does NOT improve overall survival in low-risk patients, only reduces vaginal recurrence (which is rare and often salvageable). Therefore, observation is justified. ### When Adjuvant Therapy IS Indicated Adjuvant vaginal brachytherapy is considered if ANY of these are present: - Grade 2–3 histology - Myometrial invasion >50% - LVSI present - Age >60 with grade 2 and outer third invasion (intermediate-risk) **Warning:** Do not confuse low-risk with high-risk disease. This patient's excellent prognostic features make adjuvant therapy unnecessary and potentially harmful (late effects, quality of life impact).